Repeated CBD (100 ng/0.5 ul, intra-accumbens) for five or 16 days and (in another group) immediately before a D-amphetamine-induced (100 ng/0.5 ul, intra-accumbens) model of schizophrenia in rats (n = 8–10/group) decreased D-amphetamine-induced hyperlocomotion, dopaminergic neuronal sensitization (F(3, 36) = 18.711, p < 0.001; F(5, 113) = 4.17, p < 0.01, both post hoc p < 0.05) and modified ventral tegmental area molecular pathways (e.g. mTOR and p70S6K increase t(6) =  − 3.60, p < 0.05; t(6) =  − 3.70, p < 0.05) (Renard et al. 2016). This evidence concerns the gene RPS6KB1 and schizophrenia.